Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown

Nature Reviews Clinical Oncology 2026

View at publisher

Authors: Edoardo Mannucci, Ilaria Dicembrini

DOI: 10.1038/s41571-026-01135-0

Cited by: 9

References: 154

Fields of Study & Subjects

Diabetes Treatment and Management Neuroendocrine Tumor Research Advances Neuropeptides and Animal Physiology

References 154